Episode 1: Liquid Biopsy Decoded: Data, Diagnostics, and the Future of Cancer Care

How do we move from discovery to action in the fight against cancer?

In this inaugural episode of the Decoded podcast, Dr. Jurgi Camblong speaks with Professor Umberto Malapelle, one of the leading voices in molecular diagnostics and liquid biopsy, to explore how precision data is reshaping the fight against cancer.

Together, they decode the evolving role of pathology, tracing the shift from glass slides to genomic signals and the rise of liquid biopsy as a dynamic, non-invasive tool in cancer care.

Professor Malapelle reveals how integrating molecular insights is making diagnostics more precise, accessible, and equitable—while empowering clinicians to personalize treatment at scale.

The conversation unpacks the real-world impact of liquid biopsy, the economics of molecular testing, and why the future of cancer care depends on both collaboration and a new generation of digitally fluent healthcare professionals.

Listen in for:

Insights on where cancer diagnostics is heading
The power—and challenge—of integrating complex data in medicine
Why liquid biopsy is more than a buzzword

This is the future of oncology, decoded.

Share this podcast

Meet the Minds

Dr. Jurgi Camblong

Founder and CEO, SOPHiA GENETICS

A visionary entrepreneur and molecular biologist, Dr. Camblong is leading the global shift toward data-driven medicine. With a PhD in Life Sciences from the University of Geneva, an EMBA from EPFL/HEC Lausanne, and publications in Cell, Science, and Nature, he drives innovation that empowers clinicians to improve outcomes worldwide, for millions of patients.

Professor Umberto Malapelle

Associate Professor, Department of Public Health, University Federico II of Naples and International Society for Liquid Biopsy

A global authority in molecular pathology, Professor Malapelle has helped define the standard for precision diagnostics in oncology. Through his work, he continues to bridge research and clinical practice, driving new models of care and access.

Full transcript

Read the full transcript

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur nec eleifend sapien. Donec tincidunt sem sollicitudin magna convallis, at porttitor lectus placerat. Cras congue sapien a nisl mollis laoreet. Integer ullamcorper, lectus et malesuada consectetur, neque lorem lobortis risus, finibus laoreet diam augue et ipsum. Integer elementum odio quis convallis aliquam. Praesent dolor lectus, aliquet eget justo et, rutrum condimentum mauris. Nam ullamcorper ante ac nisl pellentesque, vel tempor ex condimentum. Nam non venenatis ipsum. Sed turpis nisl, mattis id pulvinar vel, eleifend vitae lectus. Etiam aliquet ultricies hendrerit. Donec odio ante, faucibus eget risus in, gravida malesuada magna. Nullam posuere congue congue. Phasellus iaculis ante non dapibus tempor.

Duis congue dui eu diam facilisis tincidunt. Curabitur fringilla eros id luctus pretium. Suspendisse sagittis ut velit ac cursus. Aliquam in magna ac mauris interdum bibendum. Donec vitae quam interdum orci vulputate volutpat. Nulla tempor sollicitudin leo ut vehicula. Proin dictum risus vitae enim ullamcorper hendrerit. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae;

Curabitur malesuada posuere magna a consequat. Aenean hendrerit dolor ut risus rutrum, sit amet euismod eros tempus. Donec a elementum risus. Cras in sodales ligula, id pharetra quam. Curabitur porttitor nisi non tellus posuere rhoncus. Integer venenatis viverra nisl eget lacinia. Aliquam elementum enim a ante maximus pharetra. Integer sit amet lacus ullamcorper, aliquam lectus non, luctus turpis. Cras tristique orci sem, ac pretium tellus congue eu.

Phasellus gravida, ante eget consequat bibendum, erat libero porttitor arcu, eget ultricies leo felis id dui. Maecenas quis aliquam urna. Fusce at erat id ex dignissim rhoncus. Duis pharetra auctor nulla at pretium. Sed at congue urna. Curabitur sagittis commodo euismod. Aliquam nisl mauris, ultrices ut fermentum sed, dignissim quis nunc. Donec luctus, ipsum non viverra pellentesque, risus neque tempus ex, ut ullamcorper turpis est eget orci. Sed tempor egestas erat at vehicula. Nunc nunc massa, viverra vel viverra in, convallis non justo. Nulla nec nunc sed odio vulputate tincidunt. Suspendisse dapibus lorem et leo malesuada tempor. Duis consectetur tortor id magna convallis, dapibus rhoncus tellus laoreet. Aliquam vitae odio facilisis tortor tristique iaculis a nec massa. Praesent pulvinar ultrices nulla, tempor vulputate arcu suscipit ut. Pellentesque sed mattis augue.

Sed volutpat velit a mi luctus pellentesque. Curabitur a diam leo. Aenean ipsum enim, posuere ut erat in, consectetur ultrices metus. Quisque et mauris arcu. Nam feugiat sed magna quis euismod. Praesent non mattis mi. Nunc sollicitudin sed ipsum sed fermentum. Proin ut pulvinar enim. Sed ut justo turpis. Pellentesque auctor metus in elementum mollis. Aenean at tempus erat, id elementum nunc. Vestibulum et felis id sem pellentesque convallis. Duis mattis consequat erat vitae molestie. Nullam id gravida erat. Nulla volutpat id nibh sed consequat. Curabitur aliquet sapien porta erat lacinia, quis blandit elit interdum.

Show notes

[1] Donec luctus, ipsum non viverra pellentesque, risus neque tempus ex
[2] Ut ullamcorper turpis est eget orci. Sed tempor egestas erat at vehicula
[3] Nunc nunc massa, viverra vel viverra in, convallis non justo
[4] Nulla nec nunc sed odio vulputate tincidunt. Suspendisse dapibus lorem et leo malesuada tempor

Tune in now on your favorite platform

Listen to the voices shaping the future of data-driven, human-centered medicine.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

Episode 1: Liquid Biopsy Decoded: Data, Diagnostics, and the Future of Cancer Care

How do we move from discovery to action in the fight against cancer?

Share this podcast

Meet the Minds

Dr. Jurgi Camblong

Professor Umberto Malapelle

Full transcript

Show notes

Tune in now on your favorite platform

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services